$CDXS
CODEXIS, INC. Stock $cdxs

$cdxs Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000120037516000052 Filed on March 08, 2016

Income Statement

Concept	2016 Q1	2015	2014 Q4
Revenue	$7.996M	$41.80M	$14.19M
YoY Change	17.62%	18.4%	48.98%
Cost Of Revenue	$2.489M	$6.586M	$3.550M
YoY Change	70.95%	-32.28%	-25.48%
Gross Profit	$5.507M	$35.22M	$10.64M
YoY Change	3.09%	37.67%	123.48%
Gross Profit Margin	68.87%	84.25%	74.98%
Selling, General & Admin	$6.802M	$22.32M	$5.150M
YoY Change	21.94%	1.72%	-10.95%
% of Gross Profit	123.52%	63.36%	48.4%
Research & Development	$5.686M	$20.67M	$5.050M
YoY Change	7.42%	-9.15%	-42.8%
% of Gross Profit	103.25%	58.7%	47.46%
Depreciation & Amortization	$465.0K	$5.410M	$1.470M
YoY Change	-16.67%	-19.01%	-40.49%
% of Gross Profit	8.44%	15.36%	13.82%
Operating Expenses	$14.98M	$42.99M	$10.19M
YoY Change	21.5%	-21.0%	-47.41%
Operating Profit	-$6.981M	-$7.770M	$450.0K
YoY Change	26.26%	-59.34%	-103.08%
Interest Expense	$20.00K	$0.00	$0.00
YoY Change			-100.0%
% of Operating Profit			0.0%
Other Income/Expense, Net	$3.000K	$168.0K	-$50.00K
YoY Change	-88.0%	-28.21%	150.0%
Pretax Income	-$6.963M	-$7.641M	$400.0K
YoY Change	25.46%	-63.58%	-104.06%
Income Tax	$11.00K	-$338.0K	$60.00K
% Of Pretax Income			15.0%
Net Earnings	-$6.974M	-$7.581M	$350.0K
YoY Change	25.39%	-60.25%	-103.57%
Net Earnings / Revenue	-87.22%	-18.13%	2.47%
Basic Earnings Per Share
Diluted Earnings Per Share	-$173.9K	-$192.9K	$9.056K
COMMON SHARES
Basic Shares Outstanding	40.47M shares		39.55M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.20M	$23.30M	$26.49M
YoY Change	0.0%	-12.08%	5.38%
Cash & Equivalents	$22.16M	$23.30M	$26.49M
Short-Term Investments			$0.00
Other Short-Term Assets	$1.200M	$1.200M	$1.300M
YoY Change	-7.69%	-7.69%	-65.79%
Inventory	$1.021M	$1.000M	$1.395M
Prepaid Expenses
Receivables	$4.352M	$7.300M	$3.870M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$28.78M	$32.80M	$33.01M
YoY Change	4.14%	-0.61%	-7.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.756M	$3.100M	$3.995M
YoY Change	-21.23%	-22.5%	-52.7%
Goodwill	$3.241M		$3.241M
YoY Change	0.0%		0.0%
Intangibles	$1.968M		$6.186M
YoY Change	-63.16%		-35.29%
Long-Term Investments	$1.500M	$1.500M	$700.0K
YoY Change	114.29%	114.29%	-12.5%
Other Assets	$202.0K	$1.100M	$294.0K
YoY Change	-28.87%	10.0%	-3.92%
Total Long-Term Assets	$10.41M	$11.80M	$15.12M
YoY Change	-24.48%	-21.85%	-34.45%
TOTAL ASSETS
Total Short-Term Assets	$28.78M	$32.80M	$33.01M
Total Long-Term Assets	$10.41M	$11.80M	$15.12M
Total Assets	$39.19M	$44.60M	$48.12M
YoY Change	-5.39%	-7.28%	-18.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.850M	$3.400M	$4.673M
YoY Change	46.0%	-27.66%	17.98%
Accrued Expenses	$3.224M	$5.300M	$2.619M
YoY Change	56.13%	-5.36%	62.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.48M	$14.80M	$13.74M
YoY Change	38.87%	8.03%	22.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.458M	$6.900M	$2.528M
YoY Change	-40.83%	-14.81%	-49.88%
Total Long-Term Liabilities	$2.458M	$6.900M	$2.528M
YoY Change	-40.83%	-14.81%	-49.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.48M	$14.80M	$13.74M
Total Long-Term Liabilities	$2.458M	$6.900M	$2.528M
Total Liabilities	$18.94M	$21.80M	$16.26M
YoY Change	18.21%	0.0%	-6.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$290.5M		-$275.9M
YoY Change	3.19%		7.42%
Common Stock	$4.000K		$4.000K
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.11M	$22.90M	$26.31M
YoY Change
Total Liabilities & Shareholders Equity	$39.19M	$44.60M	$48.12M
YoY Change	-5.39%	-7.28%	-18.22%

Cashflow Statement

Concept	2016 Q1	2015	2014 Q4
OPERATING ACTIVITIES
Net Income	-$6.974M	-$7.581M	$350.0K
YoY Change	25.39%	-60.25%	-103.57%
Depreciation, Depletion And Amortization	$465.0K	$5.410M	$1.470M
YoY Change	-16.67%	-19.01%	-40.49%
Cash From Operating Activities	$219.0K	-$433.0K	$4.970M
YoY Change	-105.69%	-234.89%	-227.11%
INVESTING ACTIVITIES
Capital Expenditures	$265.0K	$1.199M	-$30.00K
YoY Change	409.62%	297.02%	-95.89%
Acquisitions
YoY Change
Other Investing Activities	$30.00K	-$60.00K	$0.00
YoY Change	200.0%	-101.21%	-100.0%
Cash From Investing Activities	-$238.0K	-$1.257M	-$30.00K
YoY Change	406.38%	-127.05%	-93.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.091M	-$1.524M	30.00K
YoY Change	151.96%	149.43%	-106.82%
NET CHANGE
Cash From Operating Activities	$219.0K	-$433.0K	4.970M
Cash From Investing Activities	-$238.0K	-$1.257M	-30.00K
Cash From Financing Activities	-$1.091M	-$1.524M	30.00K
Net Change In Cash	-$1.110M	-$3.214M	4.970M
YoY Change	-74.35%	-173.77%	-203.76%
FREE CASH FLOW
Cash From Operating Activities	$219.0K	-$433.0K	$4.970M
Capital Expenditures	$265.0K	$1.199M	-$30.00K
Free Cash Flow	-$46.00K	-$1.632M	$5.000M
YoY Change	-98.82%	-8689.47%	-257.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	cdxs	Accounts Receivable Royalty Past Dueand Future Payment Settlement AccountsReceivableRoyaltyPastDueandFuturePaymentSettlement	3100000	USD
CY2014Q4	cdxs	Accrued Purchase Received Not Yet Billed AccruedPurchaseReceivedNotYetBilled	612000	USD
CY2015Q4	cdxs	Accrued Purchase Received Not Yet Billed AccruedPurchaseReceivedNotYetBilled	430000	USD
CY2014Q4	cdxs	Accrued Taxes AccruedTaxes	275000	USD
CY2015Q4	cdxs	Accrued Taxes AccruedTaxes	31000	USD
CY2013	cdxs	Adjustments To Additional Paid In Capital Non Employee Share Based Compensation AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation	23000	USD
CY2014	cdxs	Adjustments To Additional Paid In Capital Non Employee Share Based Compensation AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation	12000	USD
CY2015	cdxs	Adjustments To Additional Paid In Capital Non Employee Share Based Compensation AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation	4000	USD
CY2014Q4	cdxs	Availableforsale Securities Accumulated Gross Unrealized Gainbefore Tax AvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax	125000	USD
CY2015Q4	cdxs	Availableforsale Securities Accumulated Gross Unrealized Gainbefore Tax AvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax	986000	USD
CY2014Q4	cdxs	Availableforsale Securities Accumulated Gross Unrealized Lossbefore Tax AvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax	0	USD
CY2015Q4	cdxs	Availableforsale Securities Accumulated Gross Unrealized Lossbefore Tax AvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax	0	USD
CY2013	cdxs	Classof Warrantor Right Exercisesin Period ClassofWarrantorRightExercisesinPeriod	0	shares
CY2014	cdxs	Classof Warrantor Right Exercisesin Period ClassofWarrantorRightExercisesinPeriod	0	shares
CY2015	cdxs	Classof Warrantor Right Exercisesin Period ClassofWarrantorRightExercisesinPeriod	0	shares
CY2009Q4	cdxs	Common Stock Purchased CommonStockPurchased	10000000	shares
CY2015	cdxs	Defined Contribution Plan Minimum Employee Eligibility Age DefinedContributionPlanMinimumEmployeeEligibilityAge	P18Y
CY2014Q1	cdxs	Disposal Group Including Discontinued Operation Percentof Equity Interests Heldforsale DisposalGroupIncludingDiscontinuedOperationPercentofEquityInterestsHeldforsale	1
CY2013	cdxs	Fair Value Adjustmentof Assets Heldforsale FairValueAdjustmentofAssetsHeldforsale	0	USD
CY2014	cdxs	Fair Value Adjustmentof Assets Heldforsale FairValueAdjustmentofAssetsHeldforsale	698000	USD
CY2015	cdxs	Fair Value Adjustmentof Assets Heldforsale FairValueAdjustmentofAssetsHeldforsale	0	USD
CY2015Q4	cdxs	Lease Area Space Occupancy LeaseAreaSpaceOccupancy	107200	sqft
CY2014Q4	cdxs	Lease Incentive Obligation Noncurrent LeaseIncentiveObligationNoncurrent	1735000	USD
CY2015Q4	cdxs	Lease Incentive Obligation Noncurrent LeaseIncentiveObligationNoncurrent	1310000	USD
CY2013	cdxs	Noncashtaxbenefitexpense Noncashtaxbenefitexpense	68000	USD
CY2014	cdxs	Noncashtaxbenefitexpense Noncashtaxbenefitexpense	0	USD
CY2015	cdxs	Noncashtaxbenefitexpense Noncashtaxbenefitexpense	314000	USD
CY2015	cdxs	Number Of Common Shares Fair Value NumberOfCommonSharesFairValue	10000000	shares
CY2014Q4	cdxs	Numberof Marketable Securities In Unrealized Loss Position NumberofMarketableSecuritiesInUnrealizedLossPosition	0	security
CY2015Q4	cdxs	Numberof Marketable Securities In Unrealized Loss Position NumberofMarketableSecuritiesInUnrealizedLossPosition	0	security
CY2009Q4	cdxs	Percentageof Outstanding Shares Ownedat Timeof Investment PercentageofOutstandingSharesOwnedatTimeofInvestment	0.166
CY2013	cdxs	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0	USD
CY2014	cdxs	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	3000000	USD
CY2015	cdxs	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0	USD
CY2013	cdxs	Proceedsfrom Maturityof Marketable Securities ProceedsfromMaturityofMarketableSecurities	13409000	USD
CY2014	cdxs	Proceedsfrom Maturityof Marketable Securities ProceedsfromMaturityofMarketableSecurities	0	USD
CY2015	cdxs	Proceedsfrom Maturityof Marketable Securities ProceedsfromMaturityofMarketableSecurities	0	USD
CY2009Q4	cdxs	Statutory Resale Restriction Expiry Period StatutoryResaleRestrictionExpiryPeriod	P4M
CY2013	cdxs	Stock Issued During Period Value Cancellation StockIssuedDuringPeriodValueCancellation	465000	USD
CY2014	cdxs	Stock Issued During Period Value Cancellation StockIssuedDuringPeriodValueCancellation	806000	USD
CY2015	cdxs	Stock Issued During Period Value Cancellation StockIssuedDuringPeriodValueCancellation	1813000	USD
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001200375
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40472708	shares
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	108200000	USD
CY2015	dei	Entity Registrant Name EntityRegistrantName	CODEXIS INC
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4673000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3399000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3870000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4608000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5122000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2619000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2013000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7329000	USD
CY2013	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-110000	USD
CY2014	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2000	USD
CY2015	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-142000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	405000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	302379000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305981000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4366000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	521000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	498000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31452000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32215000	USD
CY2013	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	6944000	USD
CY2014	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	3311000	USD
CY2015	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	2035000	USD
CY2013	us-gaap	Advertising Expense AdvertisingExpense	500000	USD
CY2014	us-gaap	Advertising Expense AdvertisingExpense	300000	USD
CY2015	us-gaap	Advertising Expense AdvertisingExpense	300000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	150000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	460000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	428000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	421000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	428000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	421000	USD
CY2013	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	76000	USD
CY2014	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2015	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	7000	USD
CY2013	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2014	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	43000	USD
CY2015	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3374000	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3374000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3374000	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6797000	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6268000	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6007000	shares
CY2013Q4	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1571000	USD
CY2014Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	400000	USD
CY2015Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	400000	USD
CY2013	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	0	USD
CY2014	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	0	USD
CY2014Q4	us-gaap	Assets Assets	48122000	USD
CY2015Q4	us-gaap	Assets Assets	44647000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	33007000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	32839000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	15290000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	12669000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	15165000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11683000	USD
CY2014Q4	us-gaap	Cash Cash	11885000	USD
CY2014Q4	us-gaap	Cash Cash	11900000	USD
CY2015Q4	us-gaap	Cash Cash	12153000	USD
CY2015Q4	us-gaap	Cash Cash	12200000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32003000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22130000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26487000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23273000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9873000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4357000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3214000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39761000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40636000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39563000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40343000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41199000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19181000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7034000	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	14554000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	9726000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6586000	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	73068000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	54418000	USD
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	49574000	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-45000	USD
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-371000	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-13000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-40000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-366000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-8000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-59000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-293000	USD
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	19000	USD
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	110000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-16000	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-47000	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	110000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-330000	USD
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	186000	USD
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	199000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	61000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	143000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3497000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6098000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3813000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3120000	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-7000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-21000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	933000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	933000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2697000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3357000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4639000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	5127000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	91589000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	92867000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	148000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	126000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	70666000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	70005000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	101000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	98000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2295000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2377000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4421000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4671000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2988000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3460000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2701000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2713000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	91513000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1653000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-278000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	92762000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	110000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	94000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	186000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	199000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	USD
CY2014	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000	USD
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	USD
CY2014	us-gaap	Disposal Group Not Discontinued Operation Loss Gain On Write Down DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown	-100000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.08
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2946000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3331000	USD
CY2015	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P6Y
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18690000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18966000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2812000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24876000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21778000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6186000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2812000	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	800000	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-24000	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-32000	USD
CY2013	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	USD
CY2014	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-87000	USD
CY2015	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	USD
CY2013	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	0	USD
CY2014	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	760000	USD
CY2015	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	0	USD
CY2014Q4	us-gaap	Goodwill Goodwill	3241000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	3241000	USD
CY2013	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2014	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2014	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2015	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2014	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets	698000	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1582000	USD
CY2014	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1841000	USD
CY2015	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2014Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	2200000	USD
CY2015Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	1700000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-41696000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-20980000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-7641000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	306000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2000	USD
CY2014	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-333000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-41390000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19327000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7919000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-256000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-338000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17392000	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6042000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1249000	USD
CY2013	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-108000	USD
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	447000	USD
CY2015	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	31000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-14073000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6571000	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2693000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-1272000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-364000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-43000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	117000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	77000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1948000	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	249000	USD
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1126000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	195000	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	57000	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	85000	USD
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	103000	USD
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	15000	USD
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	8000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	308000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	713000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1274000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1629000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1587000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3459000	USD
CY2014Q1	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-760000	USD
CY2013	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	2179000	USD
CY2015	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	0	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1629000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4195000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1908000	USD
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	130000	USD
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-530000	USD
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	385000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	185000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-92000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-403000	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2724000	USD
CY2014	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	555000	USD
CY2015	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1062000	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-337000	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	78000	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	16000	USD
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1857000	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-850000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	339000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-10000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-800000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	76000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1246000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	730000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1395000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	992000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	84000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	262000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	65000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	60000	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	19000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3600000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3400000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3400000	USD
CY2014Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	425000	USD
CY2015Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	425000	USD
CY2014Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	700000	USD
CY2015Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	700000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48122000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44647000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13735000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14841000	USD
CY2014Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	688000	USD
CY2015Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1549000	USD
CY2014Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	14602000	USD
CY2014Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	14600000	USD
CY2015Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11120000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-147000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-41146000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-19111000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-7770000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11295000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2827000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-611000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1524000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13272000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4647000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1257000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22998000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	321000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-433000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-41303000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-19071000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-7581000	USD
CY2015	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	2700000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	237000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2818000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2736000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2677000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2013	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	0	USD
CY2014	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	400000	USD
CY2015	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	600000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	725000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	486000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	294000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	310000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	300000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	104000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-110000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	547000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-68000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-314000	USD
CY2013	us-gaap	Other Expenses OtherExpenses	304000	USD
CY2014	us-gaap	Other Expenses OtherExpenses	234000	USD
CY2015	us-gaap	Other Expenses OtherExpenses	168000	USD
CY2015	us-gaap	Other Income Tax Expense Benefit Continuing Operations OtherIncomeTaxExpenseBenefitContinuingOperations	-300000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2528000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2497000	USD
CY2013	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	465000	USD
CY2014	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	815000	USD
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1813000	USD
CY2013	us-gaap	Revenues Revenues	31922000	USD
CY2014	us-gaap	Revenues Revenues	35307000	USD
CY2014Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	1500000	USD
CY2013	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	USD
CY2014	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	1500000	USD
CY2015	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015	us-gaap	Property Plant And Equipment Transfers And Changes PropertyPlantAndEquipmentTransfersAndChanges	0	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	386000	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	11000	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2013	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	6868000	USD
CY2014	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	14945000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1175000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	302000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1199000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1255000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1245000	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	238000	USD
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	167000	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	18000	USD
CY2013	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	0	USD
CY2014	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	282000	USD
CY2015	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	318000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	195000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	289000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	37288000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	35324000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3995000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3109000	USD
CY2014	us-gaap	Property Plant And Equipment Transfers And Changes PropertyPlantAndEquipmentTransfersAndChanges	-1841000	USD
CY2015	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	25599000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31606000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22755000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20673000	USD
CY2015	us-gaap	Revenues Revenues	41804000	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	711000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	787000	USD
CY2013Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	15	employee
CY2013	us-gaap	Restructuring Charges RestructuringCharges	800000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275930000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-283511000	USD
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	4631000	USD
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	7298000	USD
CY2015	us-gaap	Royalty Revenue RoyaltyRevenue	4829000	USD
CY2014Q1	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	400000	USD
CY2013	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	20423000	USD
CY2014	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	13064000	USD
CY2015	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	11376000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26908000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21937000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22315000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	4389000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	4620000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	5126000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.012
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.017
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.650
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.650
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.661
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7126547	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2499000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.42
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	132000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.58
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	742000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4206000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3480000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3918000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.53
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.49
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	4036000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3771000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.54
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.68
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.45
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y22D
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2252000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M28D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M22D
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	172000	shares
CY2013	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5200000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	232000	USD
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, marketable securities, and restricted cash. Cash that is not required for immediate operating needs is invested principally in money market funds. Cash and cash equivalents are invested through banks and other financial institutions in the United States, India and Netherlands. Such deposits in those countries may be in excess of insured limits.</font></div></div>
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	87000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	814000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	54000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	400000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14600000	USD
CY2014	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2015	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	318000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	195000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	289000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	78440000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	41483000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	26311000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	22879000	USD
CY2013	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	104000	USD
CY2014	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	-110000	USD
CY2015	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	547000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7429000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8306000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7838000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8152000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	257000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	29000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	-47000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	24000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1116000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	346000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	368000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	6000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	158000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	500000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1200000	USD
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38231000	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38209000	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39438000	shares
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these notes to the consolidated financial statements, the “Company,” “we,” “us,’” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We develop biocatalysts for the pharmaceutical and fine chemicals markets. Our proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biocatalysts are enzymes that initiate and/or accelerate chemical reactions. Manufacturers have historically used naturally occurring biocatalysts to produce many goods used in everyday life. However, inherent limitations in naturally occurring biocatalysts have restricted their commercial use. Our proprietary CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></font><font style="font-family:inherit;font-size:10pt;">protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, is able to overcome many of these limitations, allowing us to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. Once potentially beneficial mutations are identified through this proprietary process, combinations of these mutations can then be tested until variant enzymes have been created that exhibit marketable performance characteristics superior to competitive products. This process allows for continuous, efficient improvements to the performance of enzymes. In the past, we implemented the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform through paid collaborations with our customers. In July 2014, we entered into our first license agreement pursuant to which we granted a license to a global pharmaceutical company to use the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform for their internal development purposes. In August 2015, we entered into a second license agreement involving the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform with another global pharmaceutical company and we continue to pursue platform licensing opportunities with additional customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have commercialized our technology and products in the pharmaceuticals market, which is our primary business focus. Our customers, which include several large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also use our technology to develop biocatalysts for use in the fine chemicals market. The fine chemicals market consists of several large market verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also using our technology to develop early stage, novel therapeutic product candidates, most notably our lead program for the potential treatment of phenylketonuria ("PKU") in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient.</font></div></div>
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of marketable securities, assets held for sale, intangible assets, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001200375-16-000052-index-headers.html	Edgar Link	pending
0001200375-16-000052-index.html	Edgar Link	pending
0001200375-16-000052.txt	Edgar Link	pending
0001200375-16-000052-xbrl.zip	Edgar Link	pending
cdxs-20151231.xml	Edgar Link	completed
cdxs-20151231.xsd	Edgar Link	pending
cdxs-20151231x10k.htm	Edgar Link	pending
cdxs-20151231_cal.xml	Edgar Link	unprocessable
cdxs-20151231_def.xml	Edgar Link	unprocessable
cdxs-20151231_lab.xml	Edgar Link	unprocessable
cdxs-20151231_pre.xml	Edgar Link	unprocessable
cdxs-201512_chartx18608.jpg	Edgar Link	pending
exhibit1011dcdxs-20151231.htm	Edgar Link	pending
exhibit211cdxs-20151231.htm	Edgar Link	pending
exhibit231cdxs-20151231.htm	Edgar Link	pending
exhibit311cdxs-20151231.htm	Edgar Link	pending
exhibit312cdxs-20151231.htm	Edgar Link	pending
exhibit321cdxs-20151231.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXS
CODEXIS, INC. Stock $cdxs

2016 Q1 Form 10-K Financial Statement

#000120037516000052 Filed on March 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS CODEXIS, INC. Stock $cdxs

2016 Q1 Form 10-K Financial Statement

#000120037516000052 Filed on March 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS
CODEXIS, INC. Stock $cdxs